October 29, 2020

FDA Approval Could Be a Game-Changer for Deciphera Pharmaceuticals

As of midday Friday, the biopharma’s stock is now nearly $8 higher than it was at the end of the previous week — about a 15% jump, thanks to good news from the U.S. Food and Drug Administration (FDA) regarding its drug ripretinib, marketed under the name Qinlock. First, the FDA approved Qinlock as the first fourth-line treatment for gastrointestinal stromal tumors (GISTs) and gave it Fast Track, Breakthrough Therapy, and Orphan Drug status. That news came shortly after the FDA knocked down one of Deciphera’s competitors in the process, issuing a complete response letter denying GIST therapy candidate avapritinib, from Blueprint Medicines

Leave a Reply

Your email address will not be published. Required fields are marked *